EA201990011A1 - GLUCAGON DERIVATIVE, CONJUGATE ON ITS BASIS, CONTAINING THEIR COMPOSITION AND THEIR THERAPEUTIC APPLICATION - Google Patents

GLUCAGON DERIVATIVE, CONJUGATE ON ITS BASIS, CONTAINING THEIR COMPOSITION AND THEIR THERAPEUTIC APPLICATION

Info

Publication number
EA201990011A1
EA201990011A1 EA201990011A EA201990011A EA201990011A1 EA 201990011 A1 EA201990011 A1 EA 201990011A1 EA 201990011 A EA201990011 A EA 201990011A EA 201990011 A EA201990011 A EA 201990011A EA 201990011 A1 EA201990011 A1 EA 201990011A1
Authority
EA
Eurasian Patent Office
Prior art keywords
conjugate
basis
composition
glucagon derivative
therapeutic application
Prior art date
Application number
EA201990011A
Other languages
Russian (ru)
Inventor
Чон Гук Ким
Юн Джин Пак
Ин Юнг Чой
Сун Юб Чун
Original Assignee
Ханми Фарм. Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ханми Фарм. Ко., Лтд. filed Critical Ханми Фарм. Ко., Лтд.
Priority claimed from PCT/KR2017/006922 external-priority patent/WO2018004283A2/en
Publication of EA201990011A1 publication Critical patent/EA201990011A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Abstract

Изобретение относится к производному глюкагона, конъюгату на его основе, содержащей их композиции и к их терапевтическому применению и, в частности, применению в отношении метаболического синдрома, гипогликемии и врожденного гиперинсулинизма.The invention relates to a glucagon derivative, a conjugate based on it, compositions containing them and their therapeutic use and, in particular, their use with respect to the metabolic syndrome, hypoglycemia and congenital hyperinsulinism.

EA201990011A 2017-06-02 2017-06-29 GLUCAGON DERIVATIVE, CONJUGATE ON ITS BASIS, CONTAINING THEIR COMPOSITION AND THEIR THERAPEUTIC APPLICATION EA201990011A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170069217 2017-06-02
PCT/KR2017/006922 WO2018004283A2 (en) 2016-06-29 2017-06-29 Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof

Publications (1)

Publication Number Publication Date
EA201990011A1 true EA201990011A1 (en) 2019-06-28

Family

ID=66998684

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990011A EA201990011A1 (en) 2017-06-02 2017-06-29 GLUCAGON DERIVATIVE, CONJUGATE ON ITS BASIS, CONTAINING THEIR COMPOSITION AND THEIR THERAPEUTIC APPLICATION

Country Status (1)

Country Link
EA (1) EA201990011A1 (en)

Similar Documents

Publication Publication Date Title
CO2019003182A2 (en) Glucagon derivative, conjugate thereof, composition comprising the same and therapeutic use thereof
CL2023000198A1 (en) Glucagon derivative and a composition comprising a long-acting conjugate thereof
CL2016002269A1 (en) Allosteric modulators of the hepatitis core protein b.
CL2015000942A1 (en) Compounds of substituted benzene.
EA202191513A1 (en) REDUCING THE VISCOSITY OF PHARMACEUTICAL COMPOSITIONS
CO2017006898A2 (en) Insulin glargine / lixisenatide fixed ratio formulation
CL2016003023A1 (en) "Compounds derived from (benzyl-piperazin-1-yl) (tetrahydrofuran-carbonyl or tetrahydropyran-carbonyl) substituted, rorg modulators; pharmaceutical composition comprising them; and its use in the treatment of multiple sclerosis and ankylosing spondylitis. ” pct
EA201791716A1 (en) PHARMACEUTICAL COMPOSITION
EA201692569A1 (en) POLYMIXINS WITH LOW DEGREE OF SUBSTITUTION AND COMPOSITIONS CONTAINING THEM
EA201892376A1 (en) COMBINED COMPOSITION OF THREE ANTI-VIRUS COMPOUNDS
CO2018011420A2 (en) Liquid phosphaplatin formulations
EA201990011A1 (en) GLUCAGON DERIVATIVE, CONJUGATE ON ITS BASIS, CONTAINING THEIR COMPOSITION AND THEIR THERAPEUTIC APPLICATION
EA202091403A1 (en) 2-OXO-1-PYRROLIDINYLIMIDAZOTHIAZOLE DERIVATIVES
MA44558A1 (en) Glucagon derivative, conjugate thereof, composition comprising it and therapeutic use thereof
CR20190161A (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
EA201891848A1 (en) PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF FIBROSIS
CL2023000971A1 (en) Steroids and protein conjugates thereof.
EA201991993A1 (en) APPLICATION OF PHENYLCREATIN AS A NOOTROPIC AGENT
IT201700002235A1 (en) Composition for oral administration useful in the treatment of diabetes and metabolic syndrome in general
EA201991733A1 (en) PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY
UA118032U (en) PHARMACEUTICAL COMPOSITION
EA201791296A1 (en) COMPOSITION WITH CONTINUOUS RELATIONSHIP INSULIN GLARGIN / LIKSENENID
RU2014151103A (en) APPLICATION OF COMPOUNDS OF THE CLASS OF 1,3,4-THIADIAZIN AND THEIR PHARMACEUTICAL COMPOSITION WITH ASCORBIC ACID AS A MEANS OF CORRECTION OF EXPERIMENTAL ALLOXAN SUGAR DIABETES